Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-escalation of nalbuphine as an adjuvant to bupivacaine in paravertebral block for mastectomy
PACTR201711002797317Not yet recruiting
- Sponsor
- Fayoum University Hospital
- Start
- Dec 2017
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of nalbuphine and bupivacaine in breast cancer (3 arms), sponsored by Fayoum University Hospital. Primary endpoints: Cumulative intravenous tramadol consumption over 24 hours, Pain score at rest and 1 more. Planned start Dec 2017; status: not yet recruiting.
02
Drugs
nalbuphinebupivacaine
03
Conditions
breast cancer
Beyond the preview
Go deeper on PACTR201711002797317.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR201711002797317.